Discuss This Drug

histrelin

CHEBI:CHEBI_5739

Definition

An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, 1-benzyl-D-histidyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the diacetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.

Chemical Information

Molecular Formula
C66H86N18O12
Molecular Mass
1323.50240
Charge
0
SMILES
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1cn(Cc2ccccc2)cn1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1
InChI
InChI=1S/C66H86N18O12/c1-4-70-64(95)55-17-11-25-84(55)65(96)48(16-10-24-71-66(67)68)76-58(89)49(26-38(2)3)77-62(93)53(30-43-34-83(37-74-43)33-40-12-6-5-7-13-40)81-59(90)50(27-39-18-20-44(86)21-19-39)78-63(94)54(35-85)82-60(91)51(28-41-31-72-46-15-9-8-14-45(41)46)79-61(92)52(29-42-32-69-36-73-42)80-57(88)47-22-23-56(87)75-47/h5-9,12-15,18-21,31-32,34,36-38,47-55,72,85-86H,4,10-11,16-17,22-30,33,35H2,1-3H3,(H,69,73)(H,70,95)(H,75,87)(H,76,89)(H,77,93)(H,78,94)(H,79,92)(H,80,88)(H,81,90)(H,82,91)(H4,67,68,71)/t47-,48-,49-,50-,51-,52-,53+,54-,55-/m0/s1
InChIKey
HHXHVIJIIXKSOE-QILQGKCVSA-N

Alternative Names

  • [(im-Bzl)-D-His(6),Pro(9)-NEt]-gonadotropin releasing hormone
  • 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-1-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide
  • 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-N(tau)-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide
  • histrelin
  • histrelina
  • histreline
  • histrelinum
  • L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-N(im)-benzyl-histidyl-L-leucyl-L-arginyl-L-proline ethylamide
  • ORF 17070
  • RWJ 17070

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

DRON_00010000
50975
oboInOwl#hasDbXref
Wikipedia:Histrelin
core#notation
CHEBI:5739

Additional References

Wikipedia:Histrelin

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

has_treatment
http://purl.obolibrary.org/obo/DOID_14038
rdf-schema#domain
https://w3id.org/def/predibionto#has_side_effect28990
owl#annotatedSource
t248916
owl#someValuesFrom
t617991
oboInOwl#hasOBONamespace
chebi_ontology
brand_name_suffix
LA
DRON_00010000
50975
oboInOwl#hasDbXref
Wikipedia:Histrelin
oboInOwl#id
CHEBI:5739
core#notation
CHEBI:5739
rxcui
1740437
product_type
BULK INGREDIENT
marketing_category
BULK INGREDIENT
listing_expiration_date
20241231
dosage_form
IMPLANT
active_ingredient_strength
1 g/g
route
SUBCUTANEOUS
marketing_start_date
20070531
labeler_name
DARMERICA, LLC
manufacturer_name
ENDO USA, Inc.
pharm_class
Gonadotropin Releasing Hormone Receptor Agonists [MoA]
generic_name
histrelin acetate
product_ndc
71052-142
spl_id
1b2d0fd5-375d-4f60-e063-6294a90a7b16
active_ingredient_name
HISTRELIN ACETATE
package_ndc
71052-142-50
package_description
.5 g in 1 CONTAINER (71052-142-50)
package_marketing_start_date
17-FEB-20
brand_name
SUPPRELIN LA
brand_name_base
SUPPRELIN
application_number
NDA022058
unii
QMG7HLD1ZE
spl_set_id
d8fb000e-3cc9-4803-b71d-2cc597661977
upc
0367979002016
RO_0000087
http://purl.obolibrary.org/obo/CHEBI_63533
oboInOwl#inSubset
http://purl.obolibrary.org/obo/chebi#3_STAR
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class